Global Dry Eye Disease Market to Witness Significant Growth
Global dry eye disease market is witnessing significant growth owing to the rising prevalence of ocular disorders, increasing screen time, growing aging population, and rising awareness regarding eye health across the globe. Increasing demand for artificial tears, anti-inflammatory drugs, punctal plugs, and secretagogues for effective dry eye treatment is significantly supporting market expansion. Additionally, the growing adoption of digital devices, increasing incidence of diabetes-related eye complications, and rising availability of online pharmacies are further driving the market growth. Continuous advancements in ophthalmic therapeutics and increasing investments in eye care research are also expected to accelerate market development during the forecast period.
Browse the full report description of “Global Dry Eye Disease Market Size, Share & Trends Analysis Report, By Product (Artificial Tears, Anti-Inflammatory Drugs, Punctal Plugs, Secretagogues, and Others), By Distribution Channel (Hospital Pharmacies, Independent Pharmacies and Drug Stores, and Online Pharmacies), Forecast (2021-2027)” at https://www.omrglobal.com/industry-reports/dry-eye-disease-market-size
December 2025 – Aldeyra Therapeutics faced FDA delays for reproxalap dry eye treatment
In December 2025, Aldeyra Therapeutics announced that the FDA extended the PDUFA review date for reproxalap, its investigational dry eye disease therapy, to March 2026 after requesting additional clinical study documentation. The delay reflects ongoing regulatory evaluation of the therapy’s clinical efficacy and safety profile for chronic dry eye disease treatment. Reproxalap is being developed as a novel therapeutic option targeting ocular inflammation and irritation associated with dry eye conditions. The development highlights the increasing focus on innovative ophthalmic therapies within the growing dry eye disease treatment market.
August 2025 – Alcon commercially launched TRYPTYR™ in the United States
In August 2025, Alcon officially launched TRYPTYR™ commercially in the United States following its earlier FDA approval. The company positioned the product as a next-generation neuromodulator eye drop designed to target tear deficiency and provide rapid symptom relief for chronic dry eye patients. The launch supports the growing demand for advanced ophthalmic therapies capable of improving natural tear production and long-term ocular surface health. The commercial introduction of TRYPTYR™ also strengthens Alcon’s position in the competitive global dry eye disease treatment market.
May 2025 – Alcon received FDA approval for TRYPTYR™ for dry eye disease treatment
In May 2025, the U.S. FDA approved TRYPTYR™ (acoltremon ophthalmic solution) 0.003% developed by Alcon for the treatment of signs and symptoms of dry eye disease (DED). The therapy became the first TRPM8 receptor agonist approved for DED and demonstrated rapid natural tear production as early as Day 1 during Phase 3 clinical trials. The approval marked a significant advancement in ophthalmic treatment innovation by introducing a new mechanism of action for dry eye management. The development also reflects increasing investment in novel therapeutic approaches aimed at improving patient outcomes in chronic ocular disorders.
About OMR Global
OMR Global is a market intelligence and strategic consulting firm specializing in growth advisory, competitive intelligence, and AI-enabled business research across global B2B industries.
The company supports enterprises, investors, and technology providers with actionable insights for market entry, investment analysis, procurement strategy, commercialization, and business expansion. OMR Global combines industry expertise, primary research, analytics, and digital intelligence tools to help organizations navigate evolving market landscapes and identify growth opportunities.
OMR Digital Offerings
- Pulse Intelligence Platform – AI-powered market intelligence suite designed to deliver analyst-grade insights faster and more efficiently. Built on 12+ years of research expertise and enhanced with AI-driven analytics, Pulse helps organizations transform large volumes of market and company data into actionable intelligence within hours instead of weeks. Trusted by Fortune 500 enterprises, global investment banks, strategy consultancies, and PE & VC firms, Pulse supports strategic decision-making across investment evaluation, competitive benchmarking, AI readiness, and market positioning.
Other Offerings
- Lead Generation – Verified B2B prospect data, ICP targeting, and intent-based sales intelligence
- RFx Support – End-to-end RFP, RFI, and RFQ support with vendor benchmarking and evaluation frameworks
OMR Global delivers data-driven intelligence solutions designed to support strategic decision-making, operational efficiency, and long-term business growth.
To find out more, visit www.omrglobal.com
Contact:
Mr. Anurag Tiwari
305-308, Commerce House, Janjeerwala Square,
Indore, Madhya Pradesh 452001
India
+91-780-304-0404